Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “AZD9291”

283 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 283 results

Testing effectiveness (Phase 2)Looking for participantsNCT06109558
What this trial is testing

The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC

Who this might be right for
Non Small Cell Lung CancerRET Gene MutationMET Amplification+1 more
Hunan Province Tumor Hospital 120
Testing effectiveness (Phase 2)UnknownNCT02736513
What this trial is testing

Intracranial Activity of AZD9291 (TAGRISSO) in Advanced EGFRm NSCLC Patients With Asymptomatic Brain Metastases

Who this might be right for
Lung Cancer
Soroka University Medical Center 40
Large-scale testing (Phase 3)Active Not RecruitingNCT04765059
What this trial is testing

Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell Lung Cancer
AstraZeneca 98
Early research (Phase 1)Looking for participantsNCT04780568
What this trial is testing

Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer

Who this might be right for
Metastatic Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8+1 more
Ohio State University Comprehensive Cancer Center 24
Not applicableLooking for participantsNCT06304441
What this trial is testing

Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer

Who this might be right for
Leptomeningeal Metastasis
Guangzhou Medical University 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT05801029
What this trial is testing

Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)
AstraZeneca 60
Early research (Phase 1)Study completedNCT04798638
What this trial is testing

Assess the Effect of Food on the Pharmacokinetics of TY-9591 in Healthy Volunteers

Who this might be right for
Healthy Volunteers
TYK Medicines, Inc 16
Testing effectiveness (Phase 2)Looking for participantsNCT05528458
What this trial is testing

Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma

Who this might be right for
Lung Adenocarcinoma
Samsung Medical Center 59
Testing effectiveness (Phase 2)Active Not RecruitingNCT04606771
What this trial is testing

A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 30
Testing effectiveness (Phase 2)Study completedNCT03543683
What this trial is testing

Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLC

Who this might be right for
Non-Small Cell Lung Cancer Stage IIIBNon-small Cell Lung Cancer Stage IVEGFR T790M
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University 115
Not applicableStudy completedNCT03219970
What this trial is testing

Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.

Who this might be right for
Non-small Cell Lung Cancer
AstraZeneca 156
Early research (Phase 1)Study completedNCT05954871
What this trial is testing

Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer

Who this might be right for
Colorectal CancerNon-Small Cell Lung Cancer
Genentech, Inc. 10
Large-scale testing (Phase 3)Active Not RecruitingNCT05629234
What this trial is testing

Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T)

Who this might be right for
Cancer
AstraZeneca 37
Large-scale testing (Phase 3)Looking for participantsNCT06486142
What this trial is testing

EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study

Who this might be right for
Non-Small Cell Lung Cancer
Region Skane 200
Testing effectiveness (Phase 2)UnknownNCT03257124
What this trial is testing

Study of AZD9291 in NSCLC Patients Harboring T790M Mutation Who Failed EGFR TKI and With Brain and/or LMS

Who this might be right for
Non-Small Cell Lung Cancer With EGFR T790M MutationWith Brain and/or Leptomeningeal MetastasisFailed Tyrosine Kinase Inhibitors
Samsung Medical Center 80
Very early researchStudy completedNCT03858491
What this trial is testing

Pharmacokinetic Boosting of Osimertinib

Who this might be right for
Non Small Cell Lung Cancer
Academisch Ziekenhuis Maastricht 11
Testing effectiveness (Phase 2)Looking for participantsNCT04136535
What this trial is testing

Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC

Who this might be right for
NSCLC Stage IV
Fudan University 105
Large-scale testing (Phase 3)Study completedNCT02296125
What this trial is testing

AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
AstraZeneca 674
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07323641
What this trial is testing

Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer

Who this might be right for
Lung Non-Small Cell Carcinoma
Jonsson Comprehensive Cancer Center 60
Testing effectiveness (Phase 2)Study completedNCT02094261
What this trial is testing

Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours

Who this might be right for
Non Small Cell Lung Cancer
AstraZeneca 210
Load More Results